Drug Description in Trials / DrugBank / KEGG DRUG /

  

Search results

No. 薬物名（臨床試験情報から抽出） DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY
On map, Yellow: Drug target genes 		指定難病告示番号
10.5 mg budesonide effervescent tablet for orodispersible use1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
21 mg budesonide effervescent tablet for orodispersible use1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
31mg budesonide effervescent tablet for orodispersible use1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
42mg budesonide effervescent tablet for orodispersible use1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
55 mg Montelukast1件: Montelukast2件: D00529 ,
D08229 		1件: CYSLTR1 💬2件: Calcium signaling pathway, Neuroactive ligand-receptor interaction 💬1件: 98
6[BUL 0.5 mg]1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
7[BUL 1 mg]1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
8[CC-93538]1件: Cholecalciferol1件: D00188 1件: VDR 💬5件: Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬1件: 98
9[MEDI-563]1件: Benralizumab1件: D09874 1件: IL5RA 💬4件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, Pathways in cancer 💬5件: 44, 45, 98, 162, 299
10[NA]1件: Vedolizumab1件: D08083 2件: ITGA4,
ITGB7 💬		15件: Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer, Yersinia infection 💬25件: 3, 6, 11, 13, 14, 28, 35, 41, 46, 49, 50, 53, 62, 63, 65, 75, 79, 96, 97, 98, 222, 229, 288, 294, 299
11AK002----1件: 98
12Allergen1件: Diphenylpyraline3件: D01172 ,
D01627 ,
D07862 		1件: HRH1 💬3件: Calcium signaling pathway, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction 💬1件: 98
13Allergy immunotherapy (allergy shots)----1件: 98
14APD3341件: Arginine1件: D02982 --5件: 93, 96, 97, 98, 269
15APT-1011----1件: 98
16APT-1011 - 3 mg1件: Fluticasone propionate1件: D01708 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
17AR401959 L-arginine1件: Arginine1件: D02982 --3件: 96, 97, 98
18Arginine1件: Arginine1件: D02982 --11件: 46, 58, 67, 78, 96, 97, 98, 113, 210, 251, 299
19Barium1件: Barium---3件: 2, 19, 98
20Beclomethasone dipropionate1件: Beclomethasone dipropionate2件: D00689 ,
D07495 		1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬2件: 97, 98
21Behavioral: six-foods elimination diet1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
22Benralizumab1件: Benralizumab1件: D09874 1件: IL5RA 💬4件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, Pathways in cancer 💬5件: 44, 45, 98, 162, 299
23Bethanechol1件: Bethanechol1件: D01000 5件: CHRM1,
CHRM2,
CHRM3,
CHRM4,
CHRM5 💬		13件: Alzheimer disease, Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction, cAMP signaling pathway 💬1件: 98
24BT1件: Biomodulin T---4件: 6, 96, 97, 98
25BT-11 1000mg1件: Biomodulin T---3件: 96, 97, 98
26BT-11 500mg1件: Biomodulin T---1件: 98
27BUDESONIDE1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬9件: 66, 93, 94, 95, 96, 97, 98, 228, 299
28Budesonide 0.5 mg compresse orodispersibili1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
29Budesonide 0.5 mg orodispersible tablets1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
30Budesonide 0.5mg orodispersible tablet twice daily1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
31Budesonide 1 mg compresse orodispersibili1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
32Budesonide 1 mg orodispersible tablets1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
33Budesonide 1 mg orodispersible tablets (BUL 1 mg)1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
34Budesonide 1mg orodispersible tablet twice daily1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
35Budesonide 2 mg orodispersible tablets (BUL 2 mg)1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
36Budesonide [0.4mg/ml] viscous suspension1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
37Budesonide oral suspension1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
38Budesonide oral suspension [0.2 mg/ml]1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
39Budesonide plus Prevacid1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
40BUET 0.5 mg1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
41BUET 1 mg1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
42BUET 1mg1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
43BUET 2mg1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
44BUL 0.5 mg1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
45BUL 1 mg1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
46BUU 0.4mg/ml1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
47CALY-002----1件: 98
48CC1件: Cholecalciferol1件: D00188 1件: VDR 💬5件: Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬14件: 13, 28, 46, 49, 51, 56, 84, 85, 96, 97, 98, 162, 202, 271
49CC-935381件: Cholecalciferol1件: D00188 1件: VDR 💬5件: Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬1件: 98
50Cendakimab1件: Cholecalciferol1件: D00188 1件: VDR 💬5件: Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬1件: 98
51Citalopram1件: Citalopram2件: D00822 ,
D07704 		1件: SLC6A4 💬2件: Serotonergic synapse, Synaptic vesicle cycle 💬7件: 6, 8, 13, 18, 46, 98, 127
52Compressa effervescente 0,5 mg di budesonide per uso orodispersibile1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
53Compressa effervescente 1 mg di budesonide per uso orodispersibile1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
54Cortisol1件: Hydrocortisone1件: D00088 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬2件: 81, 98
55Cromolyn1件: Cromoglicic acid2件: D00526 ,
D07753 		--3件: 2, 85, 98
56Dexlansoprazole1件: Dexlansoprazole1件: D08903 2件: ATP4A,
ATP4B 💬		4件: Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation 💬1件: 98
57Diagnostic Test: Barium Esophagram1件: Barium---1件: 98
58Diagnostic Test: Bone Mineral Density (DEXA) scan1件: Vitamin D---1件: 98
59Diagnostic Test: Cortisol level1件: Hydrocortisone1件: D00088 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
60Diagnostic Test: Endoscopy while on study drug1件: Omeprazole4件: D00455 ,
D01207 ,
D05259 ,
D05261 		2件: ATP4A,
ATP4B 💬		4件: Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation 💬1件: 98
61Diagnostic Test: Gastrointestinal Quality of Life index1件: Omeprazole4件: D00455 ,
D01207 ,
D05259 ,
D05261 		2件: ATP4A,
ATP4B 💬		4件: Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation 💬1件: 98
62Diagnostic Test: Height measurement1件: Vitamin D---1件: 98
63Diagnostic Test: High-resolution manometry1件: Omeprazole4件: D00455 ,
D01207 ,
D05259 ,
D05261 		2件: ATP4A,
ATP4B 💬		4件: Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation 💬1件: 98
64Diagnostic Test: Physical Examination and Questionnaires1件: Barium---1件: 98
65Diagnostic Test: Retrospective evaluation of endoscopy prior to study drug1件: Omeprazole4件: D00455 ,
D01207 ,
D05259 ,
D05261 		2件: ATP4A,
ATP4B 💬		4件: Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation 💬1件: 98
66Diagnostic Test: Serum biomarkers1件: Omeprazole4件: D00455 ,
D01207 ,
D05259 ,
D05261 		2件: ATP4A,
ATP4B 💬		4件: Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation 💬1件: 98
67Diagnostic Test: Vitamin D Measurement1件: Vitamin D---1件: 98
68Dupilumab1件: Dupilumab1件: D10354 1件: IL4R 💬8件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, Inflammatory bowel disease, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation 💬4件: 51, 98, 160, 162
69Dupilumab (blinded)1件: Dupilumab1件: D10354 1件: IL4R 💬8件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, Inflammatory bowel disease, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation 💬1件: 98
70Dupilumab (open-label)1件: Dupilumab1件: D10354 1件: IL4R 💬8件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, Inflammatory bowel disease, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation 💬1件: 98
71Dupixent1件: Dupilumab1件: D10354 1件: IL4R 💬8件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, Inflammatory bowel disease, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation 💬3件: 98, 160, 162
72E0E food introduction-2nd1件: Dupilumab1件: D10354 1件: IL4R 💬8件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, Inflammatory bowel disease, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation 💬1件: 98
73EoE food introduction-1st1件: Dupilumab1件: D10354 1件: IL4R 💬8件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, Inflammatory bowel disease, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation 💬1件: 98
74EoE Food introduction-3rd dose1件: Dupilumab1件: D10354 1件: IL4R 💬8件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, Inflammatory bowel disease, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation 💬1件: 98
75ESO-1011件: Mometasone3件: D00690 ,
D03325 ,
D08227 		1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
76Esomeprazole1件: Pancrelipase1件: D05349 --8件: 13, 46, 86, 98, 107, 113, 298, 299
77EsophaCap1件: Barium---1件: 98
78Esophageal dilation----1件: 98
79Esophagogastroduodenoscopy1件: Technetium Tc-99m---1件: 98
80Etrasimod1件: Etrasimod1件: D10930 5件: S1PR1,
S1PR2,
S1PR3,
S1PR4,
S1PR5 💬		3件: FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬3件: 96, 97, 98
81Etrasimod L-arginine1件: Arginine1件: D02982 --3件: 96, 97, 98
82EUR-1100----1件: 98
83Famotidine1件: Acetaminophen1件: D00217 2件: PTGS1,
PTGS2 💬		23件: Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬6件: 6, 46, 86, 98, 107, 300
84Fasenra1件: Benralizumab1件: D09874 1件: IL5RA 💬4件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, Pathways in cancer 💬5件: 44, 45, 98, 162, 299
85Florence 30 µg/mL----1件: 98
86Florence 60 µg/mL----1件: 98
87Florence 90 µg/mL----1件: 98
88Flovent----1件: 98
89Fluticasone1件: Fluticasone1件: D07981 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬3件: 98, 228, 299
90Fluticasone MDI1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
91FLUTICASONE PROPIONATE1件: Fluticasone propionate1件: D01708 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬2件: 98, 228
92Fluticasone Propionate, 800 mcg twice daily (post 4FED failure)1件: Fluticasone propionate1件: D01708 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
93Fluticasone Propionate, 880 mcg twice daily (after 6FED failure)1件: Fluticasone propionate1件: D01708 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
94Fluticasone Propionate, USP1件: Fluticasone propionate1件: D01708 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
95Gold1件: Gold---43件: 2, 5, 6, 13, 17, 34, 35, 46, 49, 50, 53, 58, 65, 68, 76, 84, 86, 91, 93, 95, 96, 97, 98, 113, 137, 158, 162, 171, 193, 218, 222, 224, 227, 230, 235, 271, 291, 294, 296, 298, 299, 310, 318
96High dose budesonide suspension1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
97High dose budesonide tablet1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
98Honey1件: Honey1件: D06776 --3件: 57, 98, 299
99Infliximab1件: Infliximab1件: D02598 1件: TNF 💬67件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬26件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271
100Inhaled/swallowed budesonide1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
101Intraluminal Impedance1件: Sucralfate1件: D00446 --1件: 98
102Intubated with Propofol (IP)1件: Propofol1件: D00549 16件: GABRA1,
GABRA2,
GABRA3,
GABRA4,
GABRA5,
GABRA6,
GABRB1,
GABRB2,
GABRB3,
GABRD,
GABRE,
GABRG1,
GABRG2,
GABRG3,
GABRP,
GABRQ 💬		7件: GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction 💬1件: 98
103Intubated with Sevoflurane (IS)1件: Propofol1件: D00549 16件: GABRA1,
GABRA2,
GABRA3,
GABRA4,
GABRA5,
GABRA6,
GABRB1,
GABRB2,
GABRB3,
GABRD,
GABRE,
GABRG1,
GABRG2,
GABRG3,
GABRP,
GABRQ 💬		7件: GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction 💬1件: 98
104IRL201104----1件: 98
105Jorveza1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
106Jorveza 0.5 mg compresse orodispersibili1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
107Jorveza 0.5 mg orodispersible tablets1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
108Jorveza 1 mg compresse orodispersibili1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
109Jorveza 1 mg orodispersible tablets1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
110Lansoprazole1件: Lansoprazole1件: D00355 2件: ATP4A,
ATP4B 💬		4件: Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation 💬7件: 63, 71, 85, 98, 166, 222, 299
111Lirentelimab1件: Lirentelimab1件: D11906 --1件: 98
112Lirentelimab (AK002)1件: Lirentelimab1件: D11906 --1件: 98
113Loratadine1件: Rituximab1件: D02994 1件: MS4A1 💬1件: Hematopoietic cell lineage 💬4件: 13, 46, 89, 98
114Losartan1件: Losartan2件: D00357 ,
D08146 		1件: AGTR1 💬16件: AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬18件: 17, 19, 36, 46, 58, 66, 67, 85, 96, 97, 98, 113, 164, 167, 179, 215, 222, 299
115LOSARTAN POTASSIUM1件: Losartan2件: D00357 ,
D08146 		1件: AGTR1 💬16件: AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬5件: 36, 98, 167, 179, 215
116Low dose budesonide tablet1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
117MEDI-5631件: Benralizumab1件: D09874 1件: IL5RA 💬4件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, Pathways in cancer 💬5件: 44, 45, 98, 162, 299
118MEPOLIZUMAB1件: Mepolizumab1件: D04923 1件: IL5 💬13件: Allograft rejection, Asthma, Autoimmune thyroid disease, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Inflammatory bowel disease, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Pathways in cancer, T cell receptor signaling pathway, Th1 and Th2 cell differentiation 💬4件: 44, 45, 98, 162
119Mepolizumab 100 mg1件: Mepolizumab1件: D04923 1件: IL5 💬13件: Allograft rejection, Asthma, Autoimmune thyroid disease, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Inflammatory bowel disease, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Pathways in cancer, T cell receptor signaling pathway, Th1 and Th2 cell differentiation 💬1件: 98
120Mepolizumab 300 mg1件: Mepolizumab1件: D04923 1件: IL5 💬13件: Allograft rejection, Asthma, Autoimmune thyroid disease, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Inflammatory bowel disease, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Pathways in cancer, T cell receptor signaling pathway, Th1 and Th2 cell differentiation 💬1件: 98
121Milk1件: Cow milk---2件: 98, 210
122Mometasone1件: Mometasone3件: D00690 ,
D03325 ,
D08227 		1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬2件: 98, 162
123MOMETASONE FUROATE1件: Mometasone3件: D00690 ,
D03325 ,
D08227 		1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬2件: 98, 162
124MONITOR1件: Perhexiline2件: D05442 ,
D08340 		8件: CACNA1C,
CACNA1D,
CACNA1F,
CACNA1S,
CPT1A,
CPT1B,
CPT1C,
CPT2 💬		47件: AMPK signaling pathway, Adipocytokine signaling pathway, Adrenergic signaling in cardiomyocytes, Alcoholic liver disease, Aldosterone synthesis and secretion, Alzheimer disease, Amphetamine addiction, Arrhythmogenic right ventricular cardiomyopathy, Calcium signaling pathway, Carbohydrate digestion and absorption, Cardiac muscle contraction, Cellular senescence, Chemical carcinogenesis - receptor activation, Cholinergic synapse, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Dilated cardiomyopathy, Dopaminergic synapse, Fatty acid degradation, Fatty acid metabolism, GABAergic synapse, Glucagon signaling pathway, Glutamatergic synapse, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, Hypertrophic cardiomyopathy, Insulin resistance, Insulin secretion, Long-term potentiation, MAPK signaling pathway, Oxytocin signaling pathway, PPAR signaling pathway, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction, Thermogenesis, Tight junction, Type II diabetes mellitus, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬20件: 2, 11, 13, 19, 28, 46, 49, 58, 65, 70, 81, 85, 86, 98, 113, 118, 129, 298, 299, 300
125Montelukast1件: Montelukast2件: D00529 ,
D08229 		1件: CYSLTR1 💬2件: Calcium signaling pathway, Neuroactive ligand-receptor interaction 💬8件: 6, 13, 46, 61, 63, 85, 98, 228
126Montelukast/ Singulair1件: Montelukast2件: D00529 ,
D08229 		1件: CYSLTR1 💬2件: Calcium signaling pathway, Neuroactive ligand-receptor interaction 💬1件: 98
127Nasonex----1件: 98
128NIOX MINO® Airway Inflammation Monitor1件: Methamidophos---1件: 98
129Nitric Oxide1件: Nitric Oxide1件: D00074 --8件: 46, 85, 86, 98, 210, 251, 294, 299
130Novel Allergen-Specific Immune Signature Directed Approach to Dietary Elimination Therapy1件: Diphenylpyraline3件: D01172 ,
D01627 ,
D07862 		1件: HRH1 💬3件: Calcium signaling pathway, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction 💬1件: 98
131OC000459----1件: 98
132OMALIZUMAB1件: Omalizumab1件: D05251 1件: FCER1A 💬4件: Asthma, Fc epsilon RI signaling pathway, Phospholipase D signaling pathway, Sphingolipid signaling pathway 💬7件: 46, 53, 65, 98, 162, 226, 299
133Omeprazole1件: Omeprazole4件: D00455 ,
D01207 ,
D05259 ,
D05261 		2件: ATP4A,
ATP4B 💬		4件: Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation 💬16件: 6, 8, 13, 21, 46, 51, 85, 96, 97, 98, 225, 271, 282, 294, 298, 299
134Omeprazole 20 MG Oral Tablet1件: Omeprazole4件: D00455 ,
D01207 ,
D05259 ,
D05261 		2件: ATP4A,
ATP4B 💬		4件: Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation 💬1件: 98
135Omeprazole 20mg BID1件: Omeprazole4件: D00455 ,
D01207 ,
D05259 ,
D05261 		2件: ATP4A,
ATP4B 💬		4件: Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation 💬1件: 98
136Oral Budesonide1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
137Oral Budesonide Suspension (MB-9)1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
138Oral Budesonide Suspension (OBS)1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
139Oral cromolyn sodium1件: Cromoglicic acid2件: D00526 ,
D07753 		--1件: 98
140Oral Viscous Budesonide1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
141Oral Viscous Budesonide (OVB)1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
142Other: 1 Food Elimination Diet1件: Fluticasone propionate1件: D01708 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
143Other: 1 Food Elimination Diet Therapy1件: Fluticasone propionate1件: D01708 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
144Other: 4 Food Elimination Diet1件: Fluticasone propionate1件: D01708 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
145Other: 4 Food Elimination Diet (post 1FED failure)1件: Fluticasone propionate1件: D01708 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
146Other: 6 Food Elimination Diet (after 1FED failure)1件: Fluticasone propionate1件: D01708 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
147Other: 6 Food Elimination Diet Therapy1件: Fluticasone propionate1件: D01708 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
148Other: Antigen (wheat base soy sauce) spray1件: Wheat1件: D06902 --1件: 98
149Other: Assessment of medication compliance1件: Vitamin D---1件: 98
150Other: D-xylose1件: Xylose1件: D06346 --1件: 98
151Other: Elimination diet1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
152Other: Honey1件: Xanthan gum1件: D06333 --1件: 98
153Other: Medication Compliance Phone Call1件: Omeprazole4件: D00455 ,
D01207 ,
D05259 ,
D05261 		2件: ATP4A,
ATP4B 💬		4件: Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation 💬1件: 98
154Other: Oral Nitric Oxide testing1件: Nitric Oxide1件: D00074 --1件: 98
155Other: Saline----8件: 2, 6, 46, 97, 98, 256, 274, 301
156Other: Symptom Survey1件: Omeprazole4件: D00455 ,
D01207 ,
D05259 ,
D05261 		2件: ATP4A,
ATP4B 💬		4件: Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation 💬1件: 98
157Other: Xanthan Gum1件: Xanthan gum1件: D06333 --1件: 98
158Potassium1件: Acetazolamide2件: D00218 ,
D01196 		13件: CA1,
CA12,
CA13,
CA14,
CA2,
CA3,
CA4,
CA5A,
CA5B,
CA6,
CA7,
CA8,
CA9 💬		7件: Bile secretion, Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Nitrogen metabolism, Pancreatic secretion, Proximal tubule bicarbonate reclamation 💬12件: 36, 46, 66, 67, 88, 94, 98, 115, 167, 179, 215, 235
159PROPOFOL1件: Isoflurane1件: D00545 --9件: 6, 21, 22, 34, 46, 70, 84, 98, 296
160QAX5761件: Infliximab1件: D02598 1件: TNF 💬67件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬4件: 51, 85, 96, 98
161Radiation: Computerized Tomography scan1件: Technetium Tc-99m---1件: 98
162Radiation: Esophageal Barium Xray1件: Barium---1件: 98
163Radiation: Planar Images1件: Technetium Tc-99m---1件: 98
164Radiation: Single Photon Emission Computed Tomography scans1件: Technetium Tc-99m---1件: 98
165Reslizumab1件: Reslizumab1件: D08985 1件: IL5 💬13件: Allograft rejection, Asthma, Autoimmune thyroid disease, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Inflammatory bowel disease, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Pathways in cancer, T cell receptor signaling pathway, Th1 and Th2 cell differentiation 💬2件: 44, 98
166RPC4046----1件: 98
167SB-2405631件: Mepolizumab1件: D04923 1件: IL5 💬13件: Allograft rejection, Asthma, Autoimmune thyroid disease, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Inflammatory bowel disease, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Pathways in cancer, T cell receptor signaling pathway, Th1 and Th2 cell differentiation 💬3件: 44, 45, 98
168SCH55700----1件: 98
169Sevoflurane1件: Lidocaine3件: D00358 ,
D02086 ,
D08127 		5件: SCN1A,
SCN2A,
SCN3A,
SCN5A,
SCN9A 💬		3件: Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction 💬7件: 6, 21, 22, 34, 98, 225, 296
170Sirolimus1件: Cyclosporine1件: D00184 5件: PPP3CA,
PPP3CB,
PPP3CC,
PPP3R1,
PPP3R2 💬		33件: Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬36件: 6, 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 89, 98, 127, 137, 157, 158, 192, 222, 277, 278, 279, 280, 281, 283, 285, 331
171Steroid and Proton Pump Inhibitor Therapy----1件: 98
172Sucralfate1件: Sucralfate1件: D00446 --1件: 98
173Swallowed fluticasone1件: Esomeprazole4件: D01984 ,
D04056 ,
D07917 ,
D09339 		2件: ATP4A,
ATP4B 💬		4件: Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation 💬1件: 98
174Technetium Tc 99m1件: Technetium Tc-99m---2件: 46, 98
175Treat with lansoprazole 30 mg BID for 2 weeks, endoscopic examination with esophageal biopsy for patients with persistent symptoms1件: Lansoprazole1件: D00355 2件: ATP4A,
ATP4B 💬		4件: Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation 💬1件: 98
176Viaskin Milk 500 mcg1件: Cow milk---1件: 98
177Viscous/swallowed budesonide1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
178Vitamin D1件: Vitamin D---24件: 3, 13, 15, 19, 41, 43, 44, 46, 49, 50, 68, 93, 95, 96, 97, 98, 179, 222, 228, 235, 256, 274, 298, 299
179Vonoprazan1件: Metronidazole3件: D00409 ,
D05016 ,
D05017 		--2件: 63, 98
180Wheat1件: Wheat1件: D06902 --3件: 6, 98, 266
181Xanthan gum1件: Xanthan gum1件: D06333 --1件: 98
182Xylose1件: Xylose1件: D06346 --1件: 98
183Zofran - no intubation1件: Propofol1件: D00549 16件: GABRA1,
GABRA2,
GABRA3,
GABRA4,
GABRA5,
GABRA6,
GABRB1,
GABRB2,
GABRB3,
GABRD,
GABRE,
GABRG1,
GABRG2,
GABRG3,
GABRP,
GABRQ 💬		7件: GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction 💬1件: 98